| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.002 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.097 | 0.003 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.007 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.078 | 0.008 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.094 | 0.009 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.02 |